Skip to content

Fortress Biotech, Inc.: financial reference

Explore Fortress Biotech, Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Context from the filing

Fortress Biotech's 2024 and 2025 common-share EPS uses dollar thousands and full shares. The 2025 consolidated loss becomes $6.815 million of income attributable to Fortress after noncontrolling interests; $8.697 million of preferred and subsidiary deemed dividends then produces a $1.882 million common-stockholder loss. The 2024 common loss similarly includes the dividend adjustment. EPS is not calculated from consolidated loss or Fortress-attributable income alone. The filing excludes potential shares when anti-dilutive during net-loss periods. Read the source filing.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2025-12-31185,548,000USD2026-03-31
Total liabilitiesAt date2025-12-31123,365,000USD2026-03-31
Stockholders equityAt date2025-12-3149,873,000USD2026-03-31
Cash and cash equivalentsAt date2025-12-3179,381,000USD2026-03-31
Net income or loss2025-01-012025-12-316,815,000USD2026-03-31
Operating cash flow2025-01-012025-12-31-65,777,000USD2026-03-31
Capital expenditure payments2024-01-012024-12-310USD2025-03-31
Revenue2025-01-012025-12-3163,262,000USD2026-03-31
Financing cash flow2025-01-012025-12-3177,442,000USD2026-03-31
Investing cash flow2025-01-012025-12-3110,121,000USD2026-03-31
Retained earnings or deficitAt date2025-12-31-734,052,000USD2026-03-31
Basic weighted-average shares2025-01-012025-12-3127,901,889shares2026-03-31
Diluted weighted-average shares2025-01-012025-12-3127,901,889shares2026-03-31
Basic earnings per share2025-01-012025-12-31-0.07USD/shares2026-03-31
Diluted earnings per share2025-01-012025-12-31-0.07USD/shares2026-03-31
Income tax expense or benefit2025-01-012025-12-31-620,000USD2026-03-31
Net property, plant and equipmentAt date2025-12-312,519,000USD2026-03-31
Share-based compensation expense2025-01-012025-12-3128,739,000USD2026-03-31
Operating income or loss2025-01-012025-12-31-70,221,000USD2026-03-31
Current assetsAt date2025-12-31123,841,000USD2026-03-31
Interest expense2017-01-012017-12-315,860,000USD2018-03-16
Current liabilitiesAt date2025-12-3149,744,000USD2026-03-31
Current accounts payableAt date2025-12-3114,238,000USD2026-03-31
Goodwill carrying amountAt date2017-12-3118,645,000USD2018-03-16
Net finite-lived intangible assetsAt date2025-12-3127,605,000USD2026-03-31
Net current accounts receivableAt date2025-12-3129,783,000USD2026-03-31
Operating expenses2018-01-012018-12-31146,879,000USD2019-03-18
Net inventoryAt date2025-12-319,624,000USD2026-03-31
Selling, general and administrative expense2025-01-012025-12-3196,400,000USD2026-03-31
Research and development expense2023-01-012023-12-31106,071,000USD2024-03-28

Inspect the source

Entity
Fortress Biotech, Inc. / CIK 0001429260
Captured
2026-09-20T09:02:19.576Z
SEC response SHA-256
78daf3b5c8c8b3d82976f96053549696f5b6bfa1fb1158d29e0dd97a741a012d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001429260.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))